CATX Stock Summary and Trading Ideas (Perspective Therapeutics | AMEX:CATX)

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Perspective Therapeutics trades on the AMEX stock market under the symbol CATX.

As of May 26, 2026, CATX stock price climbed to $4.16 with 1,424,114 million shares trading.

CATX has a beta of 0.51, meaning it tends to be less sensitive to market movements. CATX has a correlation of 0.00 to the broad based SPY ETF.

CATX has a market cap of $474.43 million. This is considered a Small Cap stock.

Last quarter Perspective Therapeutics reported $76,000 in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-103,744 and exceeded earnings estimates by $.05.

In the last 3 years, CATX traded as high as $19.05 and as low as $1.60.

The top ETF exchange traded funds that CATX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

CATX has outperformed the market in the last year with a price return of +65.7% while the SPY ETF gained +30.0%. However, in the short term, CATX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -26.4% vs +9.1% return in SPY. But in the last 2 weeks, CATX shares have fared better than the market returning +10.6% compared to SPY +1.8%.

CATX support price is $3.79 and resistance is $4.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CATX shares will trade within this expected range on the day.